The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Long-term surveillance for cardiac toxicities in patients with HL treated with chemotherapy
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the importance of long-term surveillance for cardiac toxicities following treatment with chemotherapy in patients with Hodgkin lymphoma (HL). Patients often receive high-dose anthracycline, which has been associated with a significantly elevated risk of developing congestive cardiac failure. It is, therefore, crucial to inform patients of the risks and ensure they attend yearly cardiac follow-ups with their general practitioners (GP). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Roche, Beigene, Astra Zeneca, Abbvie, Sobi, Kite / Gilead, BMS, Pfizer, SecuraBio.
